Aquestive Therapeutics Inc (NASDAQ: AQST) is -13.20% lower on its value in year-to-date trading and has touched a low of $2.24 and a high of $6.23 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The AQST stock was last observed hovering at around $3.24 in the last trading session, with the day’s loss setting it -0.15%.
Currently trading at $3.09, the stock is -9.70% and -24.81% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.44 million and changing -4.63% at the moment leaves the stock -21.06% off its SMA200. AQST registered 16.38% gain for a year compared to 6-month gain of -0.32%. The firm has a 50-day simple moving average (SMA 50) of $4.1584 and a 200-day simple moving average (SMA200) of $3.919775.
The stock witnessed a -14.40% loss in the last 1 month and extending the period to 3 months gives it a -36.81%, and is -1.28% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.54% over the week and 6.72% over the month.
Aquestive Therapeutics Inc (AQST) has around 135 employees, a market worth around $281.74M and $58.90M in sales. Profit margin for the company is -59.75%. Distance from 52-week low is 37.95% and -50.40% from its 52-week high. The company has generated returns on investments over the last 12 months (-48.54%).
with sales reaching $13.11M over the same period.The EPS is expected to shrink by -235.90% this year, but quarterly earnings will post 13.67% year-over-year. Quarterly sales are estimated to shrink -0.71% in year-over-year returns.
152.0 institutions hold shares in Aquestive Therapeutics Inc (AQST), with institutional investors hold 59.02% of the company’s shares. The shares outstanding are 91.18M, and float is at 77.61M with Short Float at 13.51%. Institutions hold 56.06% of the Float.
The top institutional shareholder in the company is BRATTON CAPITAL MANAGEMENT, L.P. with over 9.81 million shares valued at $25.51 million. The investor’s holdings represent 13.3274 of the AQST Shares outstanding. As of 2024-06-30, the second largest holder is VR ADVISER, LLC with 5.56 million shares valued at $14.44 million to account for 7.5468 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 5.45 million shares representing 7.4099 and valued at over $14.18 million, while VANGUARD GROUP INC holds 5.743 of the shares totaling 4.23 million with a market value of $10.99 million.
Aquestive Therapeutics Inc (AQST) Insider Activity
The most recent transaction is an insider sale by Jung Cassie, the company’s Chief Operating Officer. SEC filings show that Jung Cassie sold 44 shares of the company’s common stock on Nov 26 ’24 at a price of $4.87 per share for a total of $214.0. Following the sale, the insider now owns 0.0 shares.
Aquestive Therapeutics Inc disclosed in a document filed with the SEC on Mar 15 ’24 that Schobel Alexander Mark (Chief Innovation/Tech Officer) sold a total of 50,000 shares of the company’s common stock. The trade occurred on Mar 15 ’24 and was made at $6.00 per share for $0.3 million. Following the transaction, the insider now directly holds 0.98 million shares of the AQST stock.
Still, SEC filings show that on Mar 08 ’24, Schobel Alexander Mark (Chief Innovation/Tech Officer) disposed off 25,000 shares at an average price of $5.19 for $0.13 million. The insider now directly holds 1,040,371 shares of Aquestive Therapeutics Inc (AQST).
